Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction (NCT04703842)
A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction
🩺 Plain-English Summary (8th-Grade Level)
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Who can join: Review the eligibility criteria below.
Location: San Diego Cardiac Center — San Diego, California
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- San Diego Cardiac Center — San Diego, California
- University of California, San Francisco — San Francisco, California
- Washington University in Saint Louis — St Louis, Missouri
- University of Texas Southwestern Medical Center — Dallas, Texas
- University of Washington Medicine — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 752-2941
Email: info@sardocorcorp.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Congestive Heart Failure
- SyncAV Post-Market Trial — Huntsville, Alabama
- Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study — Boston, Massachusetts
- Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure — Birmingham, Alabama
- Boston Medical Center Ultrasound Decongestion Study in Heart Failure — Boston, Massachusetts
- Palliative Care for People With HF — Indianapolis, Indiana
- Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease — Murray, Utah
Explore by condition: All Congestive Heart Failure clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.